These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29742934)

  • 21. Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients.
    Luke MC; Kozak D
    J Ocul Pharmacol Ther; 2021 Apr; 37(3):157-161. PubMed ID: 33332225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generic drugs and the prescribing physician.
    Nightingale SL; Morrison JC
    JAMA; 1987 Sep; 258(9):1200-4. PubMed ID: 3626003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical therapeutic categories: a contraindication to generic substitution?
    Colaizzi JL; Lowenthal DT
    Clin Ther; 1986; 8(4):370-9. PubMed ID: 3731208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generic Pharmaceutical Association (GPhA) - 2015 CMC Workshop (June 9-10, 2015 - Bethesda, Maryland, USA).
    Komlos D
    Drugs Today (Barc); 2015 Jul; 51(7):429-40. PubMed ID: 26261845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA critical path initiatives: opportunities for generic drug development.
    Lionberger RA
    AAPS J; 2008; 10(1):103-9. PubMed ID: 18446510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.
    Liu Q; Davit BM; Cherstniakova SA; Dandamudi S; Walters JF; Lee CH; Raines KW; Ren K; Williamson LN; Conner DP
    AAPS J; 2012 Mar; 14(1):19-22. PubMed ID: 22130775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
    Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Campbell EG
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):694-701. PubMed ID: 28370652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence testing of immunosuppressants: concepts and misconceptions.
    Christians U; Klawitter J; Clavijo CF
    Kidney Int Suppl; 2010 Mar; (115):S1-7. PubMed ID: 20150904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the bioavailability and bioequivalence of generic medications.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic substitution: issues for problematic drugs.
    Henderson JD; Esham RH
    South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 38. The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.
    Diak IL; Swank K; McCartan K; Beganovic M; Kidd J; Gada N; Kapoor R; Wolf L; Kangas L; Wyeth J; Salvatore T; Fanari M; LeBoeuf AA; Mishra P; Blum MD; Dal Pan G
    Drug Saf; 2023 Feb; 46(2):145-155. PubMed ID: 36460854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What makes a generic medication generic?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.